Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...

About a dozen activists from the Extinction Rebellion climate group briefly occupied the entrance lobby of French bank BNP ...

The U.S. Food and Drug Administration has cracked down on compounded drugs, which were readily available while the patented ones were in shortage, and many are worried they will lose access to the ...

Your commitment strengthens our ability to report fearlessly on the topics that matter most to you.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

But the FDA declared months ago that the shortages of semaglutide and tirzepatide injections had ended, effectively ending flexibilities for compounded products. The grace period for manufacturers to ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), GE Aerospace ...

Growing demand for natural weight loss solutions drives the weight management supplements market across health-conscious consumer segments.

The CMS last month declined to include anti-obesity medications in its Medicare coverage for Part D, a move that Lilly says ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...